Your browser doesn't support javascript.
Lower response to BNT162b2 vaccine in patients with myelofibrosis compared to polycythemia vera and essential thrombocythemia.
Pimpinelli, Fulvia; Marchesi, Francesco; Piaggio, Giulia; Giannarelli, Diana; Papa, Elena; Falcucci, Paolo; Spadea, Antonio; Pontone, Martina; Di Martino, Simona; Laquintana, Valentina; La Malfa, Antonia; Di Domenico, Enea Gino; Di Bella, Ornella; Falzone, Gianluca; Ensoli, Fabrizio; Vujovic, Branka; Morrone, Aldo; Ciliberto, Gennaro; Mengarelli, Andrea.
  • Pimpinelli F; Microbiology and Virology Unit, Dermatological Clinical and Research Department, IRCCS San Gallicano Institute, Rome, Italy.
  • Marchesi F; Hematology Unit, Department of Research and Clinical Oncology, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144, Rome, Italy. francesco.marchesi@ifo.gov.it.
  • Piaggio G; SAFU Unit, Department of Research and Innovative Technologies, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
  • Giannarelli D; Clinical Trial Center, Biostatistics and Bioinformatics Unit, Scientific Direction, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
  • Papa E; Hematology Unit, Department of Research and Clinical Oncology, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144, Rome, Italy.
  • Falcucci P; Hematology Unit, Department of Research and Clinical Oncology, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144, Rome, Italy.
  • Spadea A; Hematology Unit, Department of Research and Clinical Oncology, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144, Rome, Italy.
  • Pontone M; Microbiology and Virology Unit, Dermatological Clinical and Research Department, IRCCS San Gallicano Institute, Rome, Italy.
  • Di Martino S; Biological Tissue and Liquid Bank, Scientific Direction, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
  • Laquintana V; Biological Tissue and Liquid Bank, Scientific Direction, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
  • La Malfa A; Pharmacy Unit, Medical Direction, IRCCS Regina Elena National Cancer Institute and San Gallicano Institute, Rome, Italy.
  • Di Domenico EG; Microbiology and Virology Unit, Dermatological Clinical and Research Department, IRCCS San Gallicano Institute, Rome, Italy.
  • Di Bella O; Medical Direction, IRCCS Regina Elena National Cancer Institute and San Gallicano Institute, Rome, Italy.
  • Falzone G; Hematology Unit, Department of Research and Clinical Oncology, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144, Rome, Italy.
  • Ensoli F; Microbiology and Virology Unit, Dermatological Clinical and Research Department, IRCCS San Gallicano Institute, Rome, Italy.
  • Vujovic B; Medical Direction, IRCCS Regina Elena National Cancer Institute and San Gallicano Institute, Rome, Italy.
  • Morrone A; Scientific Direction, IRCCS San Gallicano Institute, Rome, Italy.
  • Ciliberto G; Scientific Direction, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
  • Mengarelli A; Hematology Unit, Department of Research and Clinical Oncology, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144, Rome, Italy.
J Hematol Oncol ; 14(1): 119, 2021 07 29.
Article in English | MEDLINE | ID: covidwho-1331948
ABSTRACT
In a population of 42 Philadelphia negative myeloproliferative neoplasm patients, all on systemic active treatment, the likelihood of responding to anti-SARS-CoV-2 BNT162b2 vaccine at 2 weeks after the second dose was significantly lower in the ten patients with myelofibrosis compared to the 32 with essential thrombocythemia (n = 17) and polycythemia vera (n = 15) grouped together, both in terms of neutralizing anti-SARS-CoV-2 IgG titers and seroprotection rates (32.47 AU/mL vs 217.97 AU/mL, p = 0.003 and 60% vs 93.8%, p = 0.021, respectively). Ruxolitinib, which was the ongoing treatment in five patients with myelofibrosis and three with polycythemia vera, may be implicated in reducing vaccine immunogenicity (p = 0.076), though large prospective study is needed to address this issue.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Polycythemia Vera / Primary Myelofibrosis / COVID-19 Vaccines / SARS-CoV-2 / COVID-19 Drug Treatment / Thrombocythemia, Essential / Antibodies, Viral Type of study: Cohort study / Observational study / Prognostic study Topics: Long Covid / Vaccines Limits: Aged / Female / Humans / Male Language: English Journal: J Hematol Oncol Journal subject: Hematology / Neoplasms Year: 2021 Document Type: Article Affiliation country: S13045-021-01130-1

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Polycythemia Vera / Primary Myelofibrosis / COVID-19 Vaccines / SARS-CoV-2 / COVID-19 Drug Treatment / Thrombocythemia, Essential / Antibodies, Viral Type of study: Cohort study / Observational study / Prognostic study Topics: Long Covid / Vaccines Limits: Aged / Female / Humans / Male Language: English Journal: J Hematol Oncol Journal subject: Hematology / Neoplasms Year: 2021 Document Type: Article Affiliation country: S13045-021-01130-1